Apixaban increases bleeding with no benefit in high-risk patients with ACS

Apixaban increases bleeding with no benefit in high-risk patients with ACS is a topic covered in the EE+ POEM Archive.

To view the entire topic, please log in or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics: